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Purpose: Annexin A2 has been shown to play a role in many neovascularization diseases. We investigated the effect of
vascular endothelial growth factor (VEGF) on annexin A2 expression and related intracellular signaling mechanisms in
a mouse model of ischemia-induced retinal neovascularization.
Methods: Annexin A2 expression and the effect of vascular endothelial growth factor (VEGF) on annexin A2 ex pression
in retinal neovascularization were assayed by real-time PCR, western blot analysis. The effect of Annexin A2 on retinal
neovascularization were assayed by siRNA interference and overexpression of Annexin A2, fluorescence imaging, and
immunofluorescence histochemistry in a mouse model of ischemia-induced retinal neovascularization.
Results: Expression of annexin A2 mRNA and protein were increased in the mouse model of ischemia-induced retinal
neovascularization and in RF/6A cells treated with VEGF. In RF/6A cells, increased expression of annexin A2 was
inhibited by the VEGF receptor 2 (VEGFR2) inhibitor SU10944, and by anti-VEGFR2 neutralizing antibody, and was
increased by VEGF. Mice with ischemic retinopathy showed increased expression of annexin A2 in vascular endothelial
cells, and enhanced retinal neovascularization after intraocular injection of an adenoviral vector containing an annexin
A2 expression cassette. Conversely, annexin A2 knockdown suppressed retinal neovascularization in these mice.
Conclusions: These findings suggest that annexin A2 might induce retinal neovascularization through a VEGF-VEGFR2
pathway in ischemia-induced retina neovascularization. Therefore, annexin A2 is an angiogenesis activator and may be
a potential target for the development of effective therapeutic strategies for the treatment of retinal neovascularization.
Retinopathy is a major complication of diabetes mellitus
and one of the leading causes of vision loss. Studies have
revealed that vascular endothelial growth factor (VEGF) is an
important element for many angiogenic processes such as
diabetic  retinopathy  and  tumor  neovascularization  [1,2].
Thus,  there  is  heightened  interest  in  understanding  the
importance of annexin A2 in regulating the retinal angiogenic
process.
The targets of VEGF are two homologous but distinct
tyrosine kinase receptors: the feline McDonough strain (fms)-
like tyrosine kinase receptor Flt-1 (VEGFR1) and the fetal
liver kinase-1 receptor Flk-1 (VEGFR2), also called KDR
[3].  Expression  of  these  receptors  increases  under
pathological conditions in which hypoxia is a main feature
[4]. VEGF binds to its receptors and stimulates a variety of
signaling  molecules,  resulting  in  promotion  of
neovascularization [5-7]. Both extracellular signal-regulated
kinase (ERK) and protein kinase C (PKC) are activated by
VEGF  and  contribute  to  the  induction  of  endothelial  cell
proliferation and migration that are essential for regulation of
angiogenesis [8,9].
Annexin A2, a cytosolic phospholipid and Ca2+ binding
protein, is a receptor of many angiogenesis-related proteins
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[10], such as angiostatin and tissue plasminogen activator (t-
PA). Annexin A2 can form heterotetrameric complexes on the
surface of endothelial cells with the annexin A2 light chain
(called S100A10 or p11), and this stimulates generation of t-
PA  dependent  plasmin  [11].  Plasmin  is  a  highly  reactive
enzyme that is physiologically involved in fibrinolysis and
plays an important role in neoangiogenesis [12]. In addition,
annexin  A2  is  a  substrate  of  PKCα,  PKCβI,  and  PKCβII
kinases in cells. Phosphorylation of annexin A2 serine 25 is
associated with its nuclear entry, DNA synthesis, and cell
proliferation [13]. However, annexin A2 has not been reported
to participate in other angiogenetic mechanisms, such as the
VEGF/VEGFR1  or  VEGF/VEGFR2  pathways  in
pathological neovascularization.
The function and regulatory role of annexin A2 in retinal
neovascularization have not been studied extensively. Here
we describe a preliminary investigation of the expression of
annexin A2, its effect on angiogenesis, and its functional
relationship  with  VEGF  in  a  mouse  model  of  ischemia-
induced retinal neovascularization model and in RF/6A cells.
METHODS
The following materials were used. Recombinant VEGF and
recombinant  VEGFR2  were  from  Strathmann  Biotech
(Hanover, Germany). Interferon-α (TNF-α), Interleukin 1-β
(IL1-β), fibroblast growth factor-2 (FGF2), placenta growth
factor (PIGF), anti–VEGF monkey mAb, and anti–VEGFR2
monkey mAb were from R&D Systems (Minneapolis, MN);
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1231calphostin C, LY333531, rottlerin, SU10944, GF1092023,
U0126,  and  PD98059  were  from  Biomol  International
(Plymouth  Meeting,  PA).  Actinomycin  D  was  from
CalBiochem (San Diego, CA), and complete mini–proteinase
inhibitor  cocktail  tablets  were  from  Roche  Diagnostic
(Mannheim, Germany). Other chemicals and reagents were
obtained from Sigma Chemical Co (St. Louis, MO). unless
otherwise indicated.
Construction  of  adenoviral  vector  expressing  mouse
annexin A2: Production of adenoviral vectors that express
mouse  annexin  A2  (Ad  annexin  A2)  has  been  described
previously  [14].  Briefly,  full-length  mouse  Annexin  A2
cDNA was amplified by PCR with the primer set of 5′-GAG
GAT CCA TGT CTA CTG TTC ACG AA-3′ and 5′-GGA
CTA  GTT  CAT  CTC  CAC  CAC  ACA-3′.  After  double
digestion with BamH I and Spe I, human annexin A2, was
cloned  into  pENTR/CMV-EGFP  vector  through
corresponding sites. The expression of the EGFP-Annexin A2
fusion protein was verified by western blot and fluorescence
microscopy. An adenovirus vector expression Kit (TaKaRa,
Ohtsu,  Japan)  was  used  to  achieve  in  vivo  homologous
recombination  between  the  transfer  cassette  bearing  the
annexin A2 expression unit and the adenovirus genome, as
well as the restriction enzyme-digested adenovirus genome
tagged with terminal protein in 293 cells. Plaque-purified
adenoviruses were propagated in 293 cells. The viral lysates
were purified and concentrated through double rounds of CsCl
step gradients.
Cell culture: The choroid-retinal endothelial cells line
RF/6Awas  obtained  from  the  cell  bank  of  the  Chinese
Academy of Science in Shanghai, China. RF/6A cells were
cultured in Ham's-F12K medium (Gibco Life Technologies,
Eggenstein,  Germany),  supplemented  with  5%  fetal  calf
serum, 100 U/ml penicillin, and 0.1 mg/ml streptomycin at
37  °C  in  a  humidified  atmosphere  of  normal  air.  Fresh
normoxic or hypoxic (degassed) medium containing 1% fetal
bovine serum (FBS) was added to the cells, and the cultures
were placed in a Therma Forma Series II water-jacketed CO2
incubator (Marietta, OH) and perfused with 1% O2, 94% N2,
5% CO2 or incubated under normoxic conditions at 37 °C for
1, 3, 6, 12, or 24 h. For VEGF and annexin A2 activity studies,
the RF/6A cells were subjected to hypoxic conditions for 2 or
4 h followed by incubation under normoxic conditions for an
additional 12 h [15].
Mouse model of hypoxia-induced ischemic retinopathy:
The model of hypoxia-induced retinopathy has been described
previously  [16].  C57BL/6J  mice  were  bought  from  the
Experimental  Animal  Center  of  Second  Military  Medical
University,  Shanghai,  China.  We  used  a  hypoxia-induced
retinopathy in which mouse pups with their nursing mothers
were exposed to 75% O2 from postnatal day 7 (P7) to P12. On
P12, mice were returned to room air for 5 days [17]. The
animals  were  maintained  in  standard  shoebox  cages  with
water and food at a constant temperature of 23±1 °C and on a
12-h light–dark cycle. Oxygen concentration was measured
with an oximeter (Toptronic, Milan, Italy). At the end of the
oxygen exposure (day 12) and 5 days after return to normoxic
conditions, the pups were killed, and retinal alterations were
observed. Mice of the same strain and of the same age were
kept in room air and used as control subjects. At various time
points, mice received intravitreous injections of siRNA or
adenoviral vector, as will be described in the paragraphs that
follow. The study protocol adhered to the ARVO Statement
for the Use of Animals in Ophthalmic and Vision Research.
Analysis of annexin A2 mRNA half-life: To determine
whether the increase in annexin A2 mRNA was caused by an
increase in transcription, RF/6A cells were exposed to 5 µg/
ml actinomycin D after 1 h of incubation with vehicle or 10
ng VEGF. The total RNA was then extracted, and real-time
PCR analysis was performed.
Real-time PCR analysis: Total RNA was isolated from
retinas and cells using an RNeasy kit (TRIzol; Invitrogen,
Carlsbad, CA). Single-stranded cDNA was synthesized from
1 µg total RNA using an oligo (dT) 18-mer as primer, and
reverse  transcription  (MMLV  Reverse  Transcriptase;
Invitrogen) in a final reaction volume of 25 µl. Real-time PCR
was performed (QuantiTect SYBR Green PCR Kit; Qiagen,
Valencia,  CA)  with  a  light-cycling  system  (LightCycler;
Roche Diagnostics GmbH, Mannheim, Germany). Primers
were described in Table 1. The value of annexin A2 mRNA
expression were normalized to GAPDH gene expression.
Western blot analysis for annexin A2 and VEGF: Mouse
eyeballs were lysed with lysis buffer that consisted of 10 mM
HEPES, pH 7.9, 10 mM potassium chloride, 0.1 mM EDTA,
1  mM  dithiothreitol,  1%  NP-40,  and  protease  inhibitor
cocktail  (Roche).  The  mice  were  anesthetized  by
intraperitoneal injection of Avertin (1.2% tribromoethanol
and  2.4%  amylene  hydrate  in  distilled  water,  0.02  ml/g
bodyweight;  Sigma-Aldrich,  St.  Louis,  MO).  Briefly,
anesthetized mice were killed by cervical dislocation, and the
eyes were rapidly removed. Next, 100 µg whole-cell extracts
were  resolved  in  10%  SDS-polyacrylamide  gels  and
electrophoretically  transferred  onto  a  polyvinylidene
difluoride membrane (Millipore, Bedford, MA). For detection
of mouse annexin A2, rabbit anti-mouse monoclonal antibody
was used. Detection was performed with HRP-conjugated
goat anti-rabbit immunoglobulins (Biosource. International,
Camarillo,  CA)  and  enhanced  chemiluminescence
(Amersham Bioscience UK Ltd., Little Chalfont, UK). After
analysis,  goat  anti-GAPDH  antibody  (I-19;  Santa  Cruz
Biotechnology, Santa Cruz, CA) was used to verify equal
protein loading and transfer.
siRNA interference in RF/6A cells and in vivo: Small
RNA of annexin A2 (Si annexin A2) was synthesized using a
Silencer siRNA Construction Kit (Ambion, Austin, TX). The
following DNA templates were used to synthesize double-
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1232stranded Si annexin A2: sense, 5′-CAA TGC ACA GAG GCA
GGA CAT-3′ and anti-sense, 5′-TTG GTT CTT GAG CAG
ATG  ATC-3′.  An  unrelated  oligonucleotide  (Si  annexin
A2_M) recognizing an irrelevant transcript was used as a
negative  control.  Transfection  was  performed  with  the
siPORT lipid transfection reagent (Ambion) following the
manufacturer’s instructions. Cells were grown subconfluently
on six-well plates and transfected with 200 nM of siRNA.
After  1  day  of  culture,  cells  were  analyzed  further  as
specifically  indicated  [18].  In  repeated  experiments,  the
experimental  results  not  showed  significant  difference
between 24 h and 48 h.
Intraocular injections: C57BL/6 mice were placed in
75% oxygen at P7, and at P12, mice (n=18) were returned to
room air and given an intravitreous injection of 1 μg of Si
annexin A2, Si annexin A2_M, Ad annexin A2, or Ad annexin
A2_N  [19].  For  siRNA  injections,  RNA  strands  were
annealed for 2 min at 94 °C in annealing buffer and siRNA
was  diluted  in  phosphate-buffered  saline  (PBS;  100  nM).
Next, 1 μl containing 1 μg of SiRNA was injected. For vectors,
1 μl containing 1010 particle units (pu) was injected. Injections
were done with a Harvard pump microinjection apparatus and
pulled glass micropipettes. Each micropipette was calibrated
to deliver 1 μl of vehicle upon depression of a foot switch.
Mice were anesthetized with 10% chloraldurat (3.5ml/kg)
given intraperitoneally, and their pupils were dilated with 1%
tropicamide eye drops. Under a dissecting microscope, the
sharpened tip of the micropipette was passed through the
mouse sclera just behind the limbus into the vitreous cavity,
and the foot switch was depressed.
Immunofluorescent  staining  for  annexin  A2:  At  P17,
mice were euthanized and eyes were removed and fixed for
30 min in 0.1 M phosphate buffer, pH 7.6, containing 5%
paraformaldehyde and 5% sucrose. After 30 min, corneas and
lenses were removed and then fixation was continued for
another hour. After washing overnight with 0.1 M phosphate
buffer containing 20% sucrose, the eyecups were frozen in
optimum cutting temperature embedding compound (Miles
Diagnostics, Elkhart, IN). Ocular frozen sections (10 µm)
were dried with cold air for 20 min, fixed in freshly prepared
4% paraformaldehyde in 0.05 M PBS at room temperature for
15 min, and rinsed with 0.05 M Tris-buffered saline (TBS) for
10  min.  Next,  10  μm  frozen  sections  were  fixed  in  5%
paraformaldehyde, and nonspecific binding was blocked by a
30 min incubation at room temperature in 10% normal goat
serum.  The  sections  were  incubated  for  1  h  at  room
temperature  with  a  1:200  rabbit  anti-mouse  monoclonal
antibody against annexin A2. Slides were washed for 3×2 min
and incubated in 1:200 fluorescein isothiocyanate (FITC) -
conjugated goat anti-rabbit (Invitrogen) for 30 min at room
temperature. After washing with PBS for 3x2 min, slides were
viewed with a Nikon fluorescence microscope.
At P15, mice reared in room air and mice with hypoxia-
induced ischemic retinopathy were euthanized. Their eyes
were rapidly removed and frozen in in an optimal cutting
temperature compound. Sodium sections (10 μm) were cut.
Frozen ocular sections were fixed with 5% paraformaldehyde
for 15 min, washed with PBS three times for 5 min, and then
immersed in chilled 50% methanol or 50% acetone for 15 min.
The sections were washed with PBS and blocked with 10%
normal goat serum for 30 min. A 1:150 dilution of rat anti-
CD31 (anti-PECAM; BD PharMingen, San Diego, CA) and
a 1:200 dilution of rabbit anti-mouse monoclonal antibody
against annexin A2 were added, and the slides were incubated
at 4 °C overnight. The sections were washed three times for 5
min, and incubated and incubated with a goat anti-rabbit IgG
conjugated with FITC and Cy3-conjugated donkey anti-rat
antibody  (Invitrogen).  After  mounting,  the  sections  were
viewed with a Nikon fluorescence microscope.
Quantification of retinal neovascularization: The eyes of
sacrificed P17 mice were enucleated and fixed for 1 h at 4 °C
with 4% paraformaldehyde. The retinas were dissected, and
stained with FITC conjugated with Griffonia Simplicifolia
Isolectin  B4  (Sigma)  for  12  h  at  4  °C  to  detect  vascular
endothelial cells. The retinas were washed with PBS for 120
min (6×20 min). Four radial cuts were made in each retina,
TABLE 1. PRIMERS USED FOR RT–PCR ANALYSIS
Gene Primers (3′-5′)
annexin A2 F: CAATGCACAGAGGCAGGACAT
R: TTGGTTCTTGAGCAGA TGATC
monkey annexin A2 F: AGCAGAGCACAGCCGTGCTA
R: TGTGGACGAGTCATACTGCG
mouse GAPDH F: CCCAGCATTCAAGAAACCATCT
R: CGACCCTGAACCTTTGAGTG
monkey GAPDH F: GTCGTGGAGTCTACTGGCGTC
R: ATGA GCCCTTCCACGATGC
Primer sequences were designed with Primer ExpressTM 2.0 (Applied Biosystems) software. Probes were labeled with 
6-carboxyfluorescein (FAM) and 6-carboxy-N,N,N´,N´- tetramethylrhodamine (TAMRA).
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1233and retinas were mounted in mounting media. Retina pictures
were taken by fluorescence microscopy and the integrity of
the  retina  image  was  restored  with  Adobe®  Photoshop®
Version  7.0  (Adobe  Systems,  San  Jose,  CA).
Neovascularization was quantified by comparing the number
of pixels in the affected areas with the total number of pixels
in the retina.
Statistical analysis: All experiments were performed at
least twice. Results are reported as mean±standard deviation.
An unpaired Student’s t-test was used to determine statistical
significance. A p<0.05 was considered significant.
Figure 1. Annexin A2 expression levels
increased in a mouse model of hypoxia-
induced  retinopathy  and  in  vitro.
Relative mRNA levels of Annexin A2
were  normalized  by  GAPDH  mRNA
levels  A:  Levels  of  annexin  A2  and
VEGF  mRNA  were  measured  by
quantitative  real-time  PCR  in  mouse
retinas  immediately  after  hypoxia
treatment (P13) and 12 h after return to
room air (P14). Double asterisks (**)
indicate  a  p<0.01  compared  with
controls. Six mice were used for each
time  point.  B:  The  figures  showed
western  blot  results  for  annexin  A2
protein in retinas from the mouse model
of  hypoxia-induced  retinopathy  (days
P12–P16). C: The figures showed the
effects  of  cytokines  factors  on  the
expression of annexin A2 mRNA. RF/
6A cells were treated respectively with
VEGF, IL1-β, TNF-α, FGF2, or PIGF at
25 ng/ml for 2 h. CN was Annexin A2
expression  levels  in  RF/6A  cells
untreated with the cytokines. Total RNA
was isolated, and quantitative real-time
PCR was used to detect the expression
of  annexin  A2  mRNA.  Results  are
representative  of  three  independent
experiments,  each  performed  with
duplicate samples. Asterisk (*) indicates
a  p<0.05  compared  with  untreated
control.
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1234Figure  2.  VEGF  induces  annexin  A2
mRNA and protein expression in a time-
dependent  and  dosage-dependent
manner in RF/6A cells. A: RF/6A cells
were treated with 25 ng/ml VEGF for
the indicated length of time. Results of
quantitative  real-time  PCR  are
representative  of  three  independent
experiments,  each  performed  with
duplicate  samples.  B:  The  protein
expression of Annexin A2 was analyzed
by western blot in RF/6A cells treated
with 25 ng/ml. VEGF for the indicated
length  of  time.  Total  cell  lysates  and
acetone-precipitated medium from cells
were  analyzed  for  the  presence  of
annexin  A2  protein.  Annexin  A2  is
indicated (arrows). The same membrane
was blotted with anti–total Akt antibody
for normalization. C: VEGF induced an
increase in annexin A2 mRNA levels
measured by quantitative real-time PCR
in  a  concentration-dependent  manner.
RF/6A  cells  were  treated  with  the
indicated concentrations of VEGF for 2
h, and then total RNA was isolated.
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To investigate whether VEGF affected the stability of
annexin A2 mRNA, we measured the half-life of annexin A2
mRNA in the presence of actinomycin D, which inhibits de
novo gene transcription. As shown in Figure 3, the half-life of
annexin A2 mRNA was 215 min in unstimulated cells and 230
min in cells treated with VEGF. There was no significant
difference between control and VEGF treatment, suggesting
that the increase in annexin A2 mRNA levels in response to
VEGF treatment was caused by transcriptional activation.
Effects  of  VEGFR2  on  VEGF-stimulated  annexin  A2
upregulation: The VEGF-induced expression levels of the
mRNA  and  protein  of  annexin  A2  respectively  were
suppressed by 87% and 75% in RF/6A cells after pretreatment
with  SU10944  (Figure  4A).  VEGF-induced  annexin  A2
expression after pretreatment of RF/6A cells with 2 µg/ml
neutralizing  antibody  against  monkey  VEGFR2  was
suppressed by 69% (Figure 4B). The results indicate that
VEGFR2 plays a major role in VEGF-induced annexin A2
expression, although we cannot exclude a role for VEGFR1.
Pretreatment of RF/6A cells with 2 µg/ml antibody against
monkey VEGF almost entirely inhibited ischemia-induced
annexin A2 expression (Figure 4C). The expression levels of
annexin A2 rose markedly in the simultaneous presence of
VEGF  and  VEGFR2  compared  with  VEGF  or  VEGFR2
singly (p<0.001).
Different  roles  of  protein  kinase  C  (PKC)  and  mitogen
activated protein kinase kinase (MEK) pathways: The role of
the PKC pathway was investigated in VEGF-induced annexin
A2  upregulation  because  PKC  is  a  well  documented
downstream target of VEGF. RF/6A cells were pretreated
with PKC inhibitors. As shown in Figure 5A,B, calphostin C
and LY333531 of PKC inhibitors inhibited VEGF-induced
upregulation  of  annexin  A2.  Inhibition  of  PKCβ  with
LY333531 reduced annexin A2 protein expression by 80%,
whereas inhibition of PKC with rottlerin resulted in only slight
inhibition,  indicating  that  a  PKC  isoform  is  involved  in
Figure 3. Effects of VEGF on annexin
A2 mRNA half-life. RF/6A cells were
treated with 25 ng/ml VEGF for 1 h.
Half  the  plates  were  returned  to
OptiMEM  plus  0.5%  FBS  without
VEGF,  and  5  µg/ml  actinomycin  D
(actD)  was  added  to  all  plates.  Total
RNA was isolated at the indicated time
points  after  actD  treatment,  and  real-
time  PCR  was  performed.
Representative  data  from  three
independent experiments are shown.
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Effects of different growth factors on annexin A2 in vivo and
in  RF/6A  cells:  Annexin  A2  mRNA  expression  was
investigated  in  the  mouse  model  of  hypoxia-induced
retinopathy. As shown in Figure 1A, VEGF mRNA levels
were  significantly  higher  in  P14  mice  than  in  P13  mice
(p<0.01). Annexin A2 mRNA levels were also significantly
increased. mRNA levels in P14 mice were approximately four
times  the  levels  in  P13  mice.  Western  blot  analysis
demonstrated that annexin A2 protein levels were elevated in
retinas from P14 to P16 compared with P13 (Figure 1B).
Several  cytokines  associated  with  angiogenesis  were
detected. Annexin A2 mRNA expression in RF/6A cells was
dramatically upregulated by VEGF and modestly upregulated
by TNF-α and IL-1β (Figure 1C). FGF2 and PIGF did not
significantly affect the expression of annexin A2 mRNA.
Effect of VEGF on annexin A2 and half-life of annexin A2
mRNA in RF/6As: Annexin A2 expression was stimulated
after treatment with 25 ng/ml VEGF. Annexin A2 mRNA
expression peaked at 6 h and persisted for 24 h after treatment
(Figure 2A). Western blot analysis showed similar results in
the cell layer and medium (Figure 2B). VEGF upregulated
annexin A2 expression in a dose-dependent manner, with a
peak effect at 25 ng/ml (Figure 2C).VEGF-induced  annexin  A2  upregulation.  The  Mitogen-
activated protein (MAP)/ERK kinase (MEK) pathway was
also investigated; two different inhibitors of MEK (U0126 or
PD98059)  failed  to  block  VEGF-induced  annexin  A2
upregulation  (Figure  5C).  Taken  together,  these  results
demonstrate that VEGF-induced annexin A2 expression was
related to PKC signaling.
Figure 4. VEGF increases annexin A2
expression through VEGFR2. A: RF/6A
cells were pretreated with 10 µM or 100
µM  SU10944  for  30  min  and  then
treated with 25 ng/ml of VEGF for 1 h.
Annexin A2 expression was detected by
real-time  PCR  and  western  blot
analysis. B: RF/6A cells were pretreated
with 2 µg/ml goat IgG or neutralizing
anti–VEGFR2 antibody for 1 h and then
stimulated with 25 ng/ml of VEGF for 1
h.  Total  RNA  was  isolated,  and
quantitative  real-time  PCR  was
performed.  C:  RF/6A  cells  were
pretreated with anti-VEGF antibody or
VEGFR2 for 1 h, and then treated with
25  ng/ml  VEGF  for1  h.  Annexin  A2
expression was detected with real-time
PCR.  Double  asterisks  (**)  represent
p<0.01  compared  with  VEGF-treated
and VEGFR2-treated samples.
Figure  5.  VEGF-induced  annexin  A2
expression  was  PKC-dependent.  A:
Serum-starved  RF/6A  cells  were
pretreated with 1 µM calphostin C, 3 µM
GF109203X, 3 µM LY333531, or 5 µM
rottlerin for 30 min and then treated with
25 ng/ml VEGF for 6 h. Annexin A2
protein  was  detected  by  western
blotting.  B:  After  overnight  serum
starvation, RF/6A cells were pretreated
with  1  µM  calphostin  C  or  2  µM
LY333531 for 30 min and then were
treated with 25 ng/ml VEGF for 2 h.
Total  RNA  was  isolated,  and
quantitative real-time PCR was used to
detect  the  expression  of  annexin  A2
mRNA. Double asterisk (**) indicates
p<0.01 compared with control samples.
C:  Serum-starved  RF/6A  cells  were
pretreated with 10 µM U0126 or 50 µM
PD98059  for  30  min  and  then  were
treated with 25 ng/ml VEGF for 6 h.
Total  cell  lysates  were  subjected  to
western blot analysis for annexin A2.
The same membrane was blotted with
anti–GAPDH  antibody  for
normalization.
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1237Annexin A2 promotes retinal neovascularization in ischemic
retina:  Annexin  A2  has  been  shown  to  promote
neovascularization in tumors [20]. To determine the effect of
annexin  A2  on  retinal  neovascularization  in  vivo,  we
employed two strategies: 1) express annexin A2 in the retinas
of  mice  with  hypoxia-induced  ischemic  retinopathy  by
intraocular injection of Ad annexin A2; and 2) intraocular
injection of Si annexin A2.
Mice  with  ischemic  retinopathy  who  received
intravitreous injections of Ad annexin A2, Ad annexin A2_N,
Si annexin A2, or Si annexin A2_M at P12 were euthanized
at P17. Immunofluorescent staining using an antibody that
specifically recognizes mouse annexin A2 showed staining
along the surface of the retina in eyes injected with Ad annexin
A2  (Figure  6A),  Ad  annexin  A2_N  (Figure  6B),  and  Si
annexin A2_M (Figure 6D), but the highest expression levels
of  annexin  A2  were  in  Ad  annexin  A2-treated  mice.
Immunofluorescent staining did not show any annexin A2 in
the retinas of Si annexin A2-treated mice (Figure 6C).
Representative  pictures  of  isolectin  B4-stained  retinal
vasculature in mice at P17 are shown in Figure 6E-H. Ad
annexin  A2-treated  mice  showed  a  marked  increase  in
multiple  neovascular  tufts,  showing  neovascularization
throughout the retina (Figure 6E). In contrast, Si annexin A2-
treated mice (Figure 6G) showed an apparent decrease in
neovascularization compared with Ad annexin A2_N (Figure
6F) and Si annexin A2_M-treated mice (Figure 6H).
Measurement of the areas of retinal neovascularization
showed that there was significantly more neovascularization
in eyes injected with Ad annexin A2 than in eyes injected with
Ad annexin A2_N. Furthermore, Si annexin A2-treated mice
had significantly smaller areas of neovascularization in their
retinas  than  Si  annexin  A2_M-treated  mice.  The
neovascularization area did not differ between the two groups
treated with Ad annexin A2_N and Si annexin A2_M (Figure
6I).
Endogenous annexin A2 was increased in endothelial cells in
ischemic retina: A polyclonal rabbit anti-murine annexin A2
antibody was used to localize endogenous annexin A2 in
mouse retinas. At P15, mice that had been reared in room air
had normal retinas and no detectable staining for annexin A2
(Figure 7A), yet retinopathy showed prominent staining that
colocalized with CD31, which selectively stains endothelial
cells  (Figure  7D).  This  indicates  that  annexin  A2  was
upregulated in vascular endothelial cells in ischemic retina
neovascularization.
DISCUSSION
In  this  study,  we  have  demonstrated  that  annexin  A2
expression is increased in the retina under hypoxic conditions.
This expression of annexin A2 is regulated by many functional
proteins, such as VEGF, VEGFR2, and PKC. Suppressing the
ischemia-induced expression of VEGFR2 with anti–VEGFR2
monoclonal  antibody,  or  of  PKC  with  PKC  inhibitors
(Calphostin C, LY333531) suppressed the increase in annexin
A2 mRNA. This suggests that VEGF, VEGFR2, and PKC
may be involved in regulating the expression of annexin A2,
and that VEGF and VEGFR2 may play major roles.
These  studies  in  vitro  show  that  the  annexin  A2
expression  of  the  mRNA  and  protein  in  RF/6A  cells  are
dramatically upregulated by VEGF (Figure 1C and Figure 2)
in a dose-dependent manner, and the increase in annexin A2
levels  of  the  mRNA  and  protein  in  response  to  VEGF
treatment was caused by transcriptional activation (Figure 3).
These indicate that annexin A2 is upregulated by VEGF in
vascular endothelial cells in ischemic retina.
Immunofluorescent  staining  with  an  antibody  that
recognizes  murine  annexin  A2  did  not  show  a  detectable
signal in normal retinas, but ischemic retinas of age-matched
mice showed staining for annexin A2 on the retina surface and
in vascular endothelial cells. This upregulation of endogenous
annexin  A2  may  not  be  a  major  factor  like  VEGF  in
encouraging retinal neovascularization, but it modulates the
response;  knockdown  of  annexin  A2  by  injection  of  Si
annexin  A2  significantly  decreased  neovascularization
compared with control eyes injected with Si annexin A2_M.
Furthermore, bolstering endogenous levels of annexin A2 by
injecting an Ad annexin A2 vector significantly increased
retinal neovascularization. Therefore, annexin A2 may act in
a positive feedback loop to help promote neovascularization
in the retina, as has been postulated for tumors [21,22].
Retinal  neovascularization  is  a  prevalent  cause  of
blindness and the focus of an intense effort to find selective
molecular treatments. This effort has received an important
boost from demonstrations that VEGF is a stimulator for both
retinal  and  choroidal  neovascularization  [23].  Retinal
ischemia (or hypoxia) is the central pathogenic feature of
retinal neovascularization and one of its major consequences
is upregulation of VEGF [24]. Retinal neovascularization is
suppressed by agents that bind VEGF [25,26] or block VEGF
receptors [27,28]. Although retinal ischemia (or hypoxia) is
the central pathogenic feature of retinal neovascularization,
VEGF  is  a  necessary  stimulator,  because  VEGF  receptor
kinase inhibitors or other agents that bind VEGF strongly
suppress retinal neovascularization [29-31]. Even though the
mechanism of the synergistic effect of annexin A2 is unknown
in ischemia retina, there is also no evidence appearing to
directly  effect  of  annexin  A2  on  VEGF;  it  may  have
synergistic  activity  in  combination  with  agents  that  bind
VEGF or by binding the mRNA of VEGF.
These data support the hypothesis that annexin A2 acts
as an activator of retinal neovascularization that is upregulated
by VEGFR2 or a conjugate of VEGF and VEGFR2 (Figure
8). This is well illustrated by the relationship between annexin
A2 and VEGF (Figure 8). In hypoxia, VEGF and annexin A2
transcription  are  upregulated  by  hypoxia  inducible  factor
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1238Figure 6. Annexin A2 promotes retinal
neovascularization  in  mice  with
ischemic retinopathy. Mice at P7 were
reared  in  75%  oxygen  for  five  days
followed by room air for five days. Eyes
of mice (n=12) were injected with (A)
Ad annexin A2, (B) Ad annexin A2_N,
(C) Si annexin A2 or (D) Ad annexin
A2_N at P12. Retinas were isolated and
stained with (A-D, scale bar represents
100 μm) FITC-antibody for annexin A2
(n=6) to detect expression of annexin
A2,  or  (G-H)  isolectin  B4  (n=6)  to
detect  neovascularization  at  P17.
Magnification  is  5X.  The  scale  bar
represents 400 μm. I: Measurement of
the  area  of  neovascularization  in  the
retina by image analysis (mm2) showed
that eyes injected with SiAnnexin A2
had  significantly  less
neovascularization  than  eyes  injected
with AdAnnexin A2.
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1239[32-34]. The biologic activity of secreted VEGF is further
influenced  by  hypoxia-inducible  expression  of  VEGFR2
[35-37].  At  the  same  time,  VEGF  directly  effect  on  the
expression of annexin A2, or a combination of VEGF and
VEGFR2 induces the expression of annexin A2. Annexin A2
is  a  substrate  protein  of  PKC.  Activation  of  annexin  A2
phosphorylation is promoted by the PKC signaling pathway
which  promote  ischemic  retina  neovascularization.
Otherwise, serine 25 phosphorylation of annexin A2 may be
associated  with  the  nuclear  entry  of  annexin  A2,  mRNA
expression  of  VEGF,  and  endothelial  cell  proliferation.
Therefore, on one hand, annexin A2 as one of the receptors
Figure 7. The annexin A2 expression in vascular endothelial cells . At P15, mice reared in room air (A, E, C) or mice with hypoxia-induced
retinopathy (B, D, F) were killed (n=6), and ocular frozen sections were stained with a rat antibody directed against CD31 or a rabbit anti-
murine annexin A2 antibody (B, D, F). Secondary antibodies were a goat anti-rabbit IgG conjugated with FITC and a Cy3-conjugated donkey
anti-rat antibody. Small cross-sections of retinal vessels are evident in the CD31-stained retina (red) from a normal mouse, while dilated
vessels and new vessels can be seen in the CD31-stained retina from a mouse with ischemic retinopathy. There is no detectable staining for
annexin A2 in the retina of the mouse reared in room air, but there is prominent staining in the retina of the mouse with ischemic retinopathy
(green). Merging of the images for the retina of the mouse with ischemic retinopathy (bottom, right) by simultaneously viewing with the red
and green channels, demonstrates colocalization of CD31 and annexin A2, indicating that annexin A2 is expressed in vascular endothelial
cells. Scale bar represents 100 μm.
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1240for plasminogen and tPA is involved in the angiogenic process
[38]. On the other hand, presumably annexin A2 as a mRNA
binding protein influences the stability of mRNA expression
of VEGF, or is involved in the angiogenic process by VEGF/
VEGFR pathway.
In  summary,  we  have  demonstrated  that  increased
expression of annexin A2 in ischemic retinas is induced by
increased levels of VEGF mRNA. This inductive effect of
VEGF for annexin A2 is mainly regulated by the expression
level of VEGFR2 mRNA. Blocking the ischemia-induced rise
in annexin A2 mRNA with Si annexin A2 also inhibits retinal
neovascularization  in  ischemic  retinas.  Together  our  data
clearly identify annexin A2 as a new functional protein in
VEGF expression in retinal neovascularization induced by
hypoxia. Compelling evidence from the literature and our own
findings suggest that annexin A2 may be a potential target for
the development of effective therapeutic strategies for the
treatment of retinal neovascularization.
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